Trending

NSCLC

Groundbreaking lung cancer approval a big boost for AZ’s Imfinzi

Groundbreaking lung cancer approval a big boost for AZ’s Imfinzi

AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients.

X

Groundbreaking lung cancer approval a big boost for AZ’s Imfinzi

https://pharmaphorum.com/news/groundbreaking-lung-cancer-approval-big-boost-azs-imfinzi/

BMS strikes back with lung cancer combo success

BMS strikes back with lung cancer combo success

Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.

X

BMS strikes back with lung cancer combo success

https://pharmaphorum.com/news/bms-strikes-back-lung-cancer-combo-success/

Roche pays $1.7 billion for cancer specialist Ignyta

Roche pays $1.7 billion for cancer specialist Ignyta

Roche is to bolster its cancer pipeline with the $1.7 billion acquisition of Ignyta. The San Diego based

X

Roche pays $1.7 billion for cancer specialist Ignyta

https://pharmaphorum.com/news/roche-pays-1-7-billion-cancer-specialist-ignyta/

Lilly’s Verzenio fails in KRAS-mutated lung cancer

Lilly’s Verzenio fails in KRAS-mutated lung cancer

Lilly’s Verzenio has failed to show benefits in lung cancer patients with a KRAS mutation, denting the company’s

X

Lilly’s Verzenio fails in KRAS-mutated lung cancer

https://pharmaphorum.com/news/verzenio-fails-lung-cancer/

Interview: AZ’s immunotherapy gamble starts to pay off

Interview: AZ’s immunotherapy gamble starts to pay off

Robert Iannone, AstraZeneca’s head of immune-oncology research, on the unpredictable immunotherapy market.

X

Interview: AZ’s immunotherapy gamble starts to pay off

https://pharmaphorum.com/views-and-analysis/az-immunotherapy-gamble-pays-off/

Tagrisso on target to be EGFR+ lung cancer standard

Tagrisso on target to be EGFR+ lung cancer standard

New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in

X

Tagrisso on target to be EGFR+ lung cancer standard

https://pharmaphorum.com/news/tagrisso-target-egfr-lung-cancer-standard/

Roche’s Alecensa shows big benefit in brain mets, advanced lung cancer

Roche’s Alecensa shows big benefit in brain mets, advanced lung cancer

Roche’s Alecensa has shown strong results in two studies looking at its benefits in ALK positive non-small cell lung cancer (NSCLC) patients, both in first line use and a second line setting.

X

Roche’s Alecensa shows big benefit in brain mets, advanced lung cancer

https://pharmaphorum.com/news/roches-alecensa-shows-big-benefit-brain-mets-advanced-lung-cancer/

Evolving immunotherapy strategies in NSCLC

Evolving immunotherapy strategies in NSCLC

Status of immunotherapies in non-small cell lung cancer (NSCLC).

X

Evolving immunotherapy strategies in NSCLC

https://pharmaphorum.com/views-and-analysis/evolving-immunotherapy-strategies-nsclc/

Roche raises outlook for 2017 following strong launches

Roche raises outlook for 2017 following strong launches

The launch of three new products with blockbuster potential helped increase Roche’s revenues 5% in the second quarter,

X

Roche raises outlook for 2017 following strong launches

https://pharmaphorum.com/news/roche-raises-outlook-2017-following-strong-launches/

1 2 3

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com